A five-day course of dirithromycin in the treatment of acute exacerbation of severe chronic obstructive pulmonary disease

Journal of Chemotherapy

Volumn 9, Issue 4, 1997, Pages 279-284

  Cazzola, M ^a,d   Caputi, M ^b   Santangelo, G ^a   Vinciguerra, A ^a   Di Perna, F ^a   Polverino, M ^c  

^a CARDARELLI HOSPITAL   (Italy)

^b SECOND UNIVERSITY OF NAPLES   (Italy)

^c S Maria dell'Olmo Hospital   (Italy)

^d NONE   (Italy)

Author keywords

Acute exacerbation of severe chronic obstructive pulmonary disease; Dirithromycin; Haemophilus influenzae

Indexed keywords

DIRITHROMYCIN;

ACUTE DISEASE; ADULT; AGED; ARTICLE; BACTERIUM ISOLATION; CHRONIC OBSTRUCTIVE LUNG DISEASE; CLINICAL ARTICLE; CLINICAL TRIAL; DISEASE SEVERITY; DRUG EFFICACY; DRUG TOLERABILITY; FEMALE; GASTROINTESTINAL SYMPTOM; HAEMOPHILUS INFLUENZAE; HUMAN; MALE; ORAL DRUG ADMINISTRATION; PSEUDOMONAS AERUGINOSA; SPUTUM ANALYSIS; STOMACH PAIN;

EID: 0030741155     PISSN: 1120009X     EISSN: None     Source Type: Journal    
DOI: 10.1179/joc.1997.9.4.279     Document Type: Article

References (29)

1. Bull P. Infective pathogencsis and outcomes in chronic bronchitis. Curr Opin Pulm Med 1996; 2: 181-185.
2. Clazzola M. Problems and prospectives in the antibiotic treatment of lower respiratory tract infections. Pulm Pharmacol 1994; 7: 139-152.
3. Anthonisen NR, Manfreda J, Warren CPW, Hershfeild ES, Harding GKM, Nelson NA. Antibiotic therapy in acute exacerbations of chronic obstructive pulmonary disease. Ann Intern Med 1987; 106: 196-204.
4. Allegra L, Grassi C, Grossi E, Pozzi E. Ruolo degli antibiotici nel trattamento della riacutizzazione della bronchite cronica. G It Mal Tor 1991; 45: 138-148.
5. Saint S, Bent S, Vittinghof E, Grady D. Antibiotics in chronic obstructive pulmonary disease exacerbations. JAMA 1995; 273: 957-960.
6. Siafakas NM, Vermeire P, Pride NB, et al. Optimal assessment and management of chronic obstructive pulmonary disease (COPD). Lur Respir J 1995; 8: 1398-1420.
7. Cazzola M, Diamare F, Di Perna F, Allegra L. Il ruolo degli inibitori delle β-lattamasi nelle infezioni del tratto respiratorio inferiore. Rass Pat App Respir 1996; 11: 26-39.
8. Westerberg SC, Smith CB, Renzetti AD. Mycoplasma infections in patients with chronic obstructive pulmonary disease. J Infect Dis 1973; 127: 491-497.
9. Cosentini R, Blasi F. New pathogens for respiratory infections. Curr Opin Pulm Med 1996; 2: 174-180.
10. Baiter MS. Recommendations on the management of chronic bronchitis. Can Med Ass J 1994; 151 (Suppl): 1-23.
11. Sides GD, Cerimele BJ, Black HR, Busch U, DeSante KA. Pharmacokinetics of dirithromycin. J Antimicrob Chemother 1993; 31 (Suppl C): 65-75.
12. DeSante KA. Human pharmacokinetics and bioavailability of dirithromycin. Drugs Today 1995; 31 (Suppl C): 11-16.
13. Bergogne-Bérézin E. Tissue distribution of dirithromycin: comparison with erythromycin. J Antimicrob Chemother 1993; 31 (Suppl C): 77-87.
14. Cazzola M. Pulmonary pharmacokinetics of dirithromycin allow a 5-day treatment of acute bacterial exacerbation of chronic bronchitis. Drugs Today 1995; 31 (Suppl. C): 17-21.
15. Matera MCS, Tufano MA, Polverino M, Rossi F, Cazzola M. Pulmonary concentrations of dirithromycin and erythromycin during acute exacerbation of mild chronic obstructive pulmonary disease. Eur Respir J 1997; 10: 97-102.
16. Sides GD. Clinical efficacy of dirithromycin in acute exacerbation of chronic bronchitis. J Antimicrob Chemother 1993; 31 (Suppl C): 131-138.
17. Gaillat J. A multicentre study comparing the safety and efficacy of dirithromycn with erythromycin in the treatment of bronchitis. J Antimicrob Chemother 1993; 31 (Suppl C): 139-151.
18. Pozzi E. Clinical efficacy of dirithromycin versus miocamycin in acute exacerbation of chronic bronchitis. J Antimicrob Chemother 1993; 31 (Suppl C): 153-158.
19. Cazzola M, Matera MG, Tufano MA, Polverino M, Catalanotti P, Varanese L, Rossi F. Pulmonary penetration of dirithromycin in patients suffering from acute exacerbation of chronic bronchitis. Pulm Pharmacol 1994; 7: 377-381.
20. Ball P, Harris JM, Lowson D, Tillotson G, Wilson R. Acute infective exacerbations of chronic bronchitis. Q J Med 1991; 88: 61-68.
21. Chodosh S. Examination of sputum cells. N Engl J Med 1970; 282: 854-857.
22. National Committee for Clinical Laboratory Standards. Methods for dilution antimicrobial susceptibility tests for bacteria that grow aerobically. 2nd ed. Approved standard M7 A2. Villanova, PA: NCCLS, 1990.
23. Lode H, Boeckh M, Schaberg T. Human pharmacokinetics of macrolide antibiotics. In: Bryskier AJ, Butzler J-P, Neu HC, Tulkens PM, eds. Macrolides. Chemistry, pharmacology and clinical uses. Paris: Arnette-Blackwell, 1993: 409-420.
24. Neu HC. Activity of macrolides against common pathogens in vitro. In: Bryskier AJ, Butzler J-P, Neu HC, Tulkens PM, eds. Macrolides. Chemistry, pharmacology and clinical uses. Paris: Arnette-Blackwell, 1993: 167-182.
25. Derriennic M. Antimicrobial activity of dirithromycin. Drugs Today 1995; 31 (suppl C): 23-28.
26. Leroyer C, Boussac J, Lode H, Smits JPH, Sides G. A comparison of 5 days of dirithromycin and 7 days of roxithromycin in acute bacterial exacerbation of chronic bronchitis. Immunol Infect Dis 1995; 5: 149-155.
27. Hosic J, Quinn P, Smits P, Sides G. A comparison of 5 days of dirithromycin and 7 days of clarithromycin in acute bacterial exacerbation of chronic bronchitis. J Antimicrob Chemother 1995; 36: 173-185.
28. Schito GC, Grazi G, Dainelli B, et al. Incidence of lower tract infections caused by mycoplasma, chlamydia and Legionella: an Italian multicenter survey. J Chemother 1994; 6: 319-321.
29. Bergogne-Bérézin L, Stotka JL. Clinical studies of dirithromycin. Drugs Today 1995; 31 (suppl C): 29-36.